Teva’s deutetrabenazine fails in paediatric Tourette syndrome trials

Teva’s deutetrabenazine is indicated in the US to treat tardive dyskinesia in adults, and Huntington’s disease-related chorea. Credit: Open Grid Scheduler / Grid Engine.